Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®
| العنوان: | Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest® |
|---|---|
| المؤلفون: | Lisette J. Saveur, Wieke H. M. Verbeek, Catharina M. Korse, Mark J C van Treijen, Dennis van der Zee, Gerlof D. Valk, Margot E. T. Tesselaar, Birthe C. Heeres, Menno R. Vriens, Femke C.R. Staal, Monique Maas |
| المصدر: | Neuroendocrinology. 111:586-598 |
| بيانات النشر: | S. Karger AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Oncology, endocrine system, medicine.medical_specialty, Validation study, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Neuroendocrine tumors, 030218 nuclear medicine & medical imaging, Disease course, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Text mining, Predictive Value of Tests, Stomach Neoplasms, Internal medicine, Intestinal Neoplasms, Biomarkers, Tumor, Humans, Medicine, Liquid biopsy, Aged, Gastroenteropancreatic neuroendocrine tumor, Aged, 80 and over, biology, Endocrine and Autonomic Systems, business.industry, Chromogranin A, Middle Aged, Prognosis, medicine.disease, Progression-Free Survival, Pancreatic Neoplasms, Neuroendocrine Tumors, biology.protein, Biological Assay, Female, business, Watchful waiting, Follow-Up Studies |
| الوصف: | Reliable prediction of disease status is a major challenge in managing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aim of the study was to validate the NETest®, a blood molecular genomic analysis, for predicting the course of disease in individual patients compared to chromogranin A (CgA). NETest® score (normal ≤20%) and CgA level (normal p = ns). The optimal cutoffs for predicting SD/PD were 33% for the NETest® and 140 µg/L for CgA. Multivariate analyses identified NETest® as the strongest predictor for PD (odds ratio: 5.7 [score: 34–79%]; 12.6 [score: ≥80%]) compared to CgA (odds ratio: 3.0), tumor grade (odds ratio: 3.1), or liver metastasis (odds ratio: 7.7). The NETest® NPV for SD was 87% at 12 months. The PPV for PD was 47 and 64% (scores 34–79% and ≥80%, respectively). NETest® metrics were comparable in the watchful waiting, treatment, and no evidence of disease (NED) subgroups. For CgA (>140 ng/mL), NPV and PPV were 83 and 52%. CgA could not predict PD in the watchful waiting or NED subgroups. The NETest® reliably predicted SD and was the strongest predictor of PD. CgA had lower utility. The NETest® anticipates RECIST-defined disease status up to 1 year before imaging alterations are apparent. |
| تدمد: | 1423-0194 0028-3835 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0bb761cab1991aa4dd808e62d36d9b0Test https://doi.org/10.1159/000509091Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c0bb761cab1991aa4dd808e62d36d9b0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14230194 00283835 |
|---|